New screening method set to speed up drug discovery in major diseases
pharmafile | July 8, 2021 | News story | | drug discovery
Scientists from the University of Birmingham and the University of Leicester have discovered a new screening method that can test the effectiveness of therapeutic molecules designed to ‘glue’ proteins together in the body.
The research paves the way for drug developers to screen large numbers of potential new drug compounds to discover new treatments for diseases such as breast cancer and Parkinson’s disease.
The study was run by researchers from the University of Birmingham’s School of Biosciences department alongside chemical biologists at the University of Leicester. They designed and tested a system that uses mass spectrometry to measure the precise mass of a pair of proteins, plus the ‘glue’, to identify which ‘glue’ is the strongest and thus will likely be the most successful in treating the disease.
Lead author, Dr Aneika Leney, said: “A healthy body depends very much on the cells’ proteins being able to signal effectively. Any wrong signal can lead to disease and that could be the wrong proteins sticking together – or proteins not joining up as they should. We want a drug that corrects for this. Our methods provide a ‘snapshot’ of what is happening to the proteins when we add a potential drug so we can see quickly whether the ‘glue’ is working.”
The ways in which proteins interact with each other are fundamental to all cell functions. These interactions underpin every function of a healthy body, with any slight change in these interactions resulting in disease.
A handful of drugs have been designed that can break apart these interactions, and this serves to disrupt the progress of the disease. However, in some diseases, the problem is caused by protein interactions not happening, or not happening in the right way. So new drugs that work by ‘gluing’ these proteins together would be highly effective, but finding them is not straightforward.
Dr Doveston, from the University of Leicester, said: “Looking for molecules that act as glues is not easy because things are complicated by having two proteins in the mix. At the early stage of development we often just want to find molecules that are good starting points for development, so they might not be that good as glues at this stage. The current high-throughput screening methods available to us are usually not very effective in this context. The mass spectrometry method is great because we can learn so much from the data and it can be gathered relatively easily and quickly.
“Because the glue compounds are highly specific to the identified proteins, interactions with other proteins are rare, so the therapy is unlikely to produce any unlooked-for effects.”
Dr Leney added: “We hope our approach will be taken up by pharmaceutical companies and used to rapidly screen and test promising drug compounds that can bind proteins together to deliver a therapeutic benefit.”
Kat Jenkins
Related Content
Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University
Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital …
Certara to acquire Chemaxon for drug discovery portfolio
Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara …
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
